Trial reportEuropean journal of clinical pharmacology2009
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Trial report in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 80 citations in OpenAlex.
- Trial
- The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines.BMC neurology · 2025Trial
- Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.European journal of neurology · 2025Trial
- Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Trial
- Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).British journal of clinical pharmacology · 2019Trial
- Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.Neurology · 2019Trial
- Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.Clinical pharmacokinetics · 2013Trial
- The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.European journal of clinical pharmacology · 2012Trial
- Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2011Trial
- Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996) · 2010Trial
- COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Subcutaneous Levodopa: A New Engine for the Vintage Molecule.Neurology and therapy · 2024Review
- Biosensor Strip for Rapid On-site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease.Angewandte Chemie (International ed. in English) · 2024Article
- [Relevance of COMT inhibitors in the treatment of motor fluctuations].Der Nervenarzt · 2022Review
- Article
- Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- From medications to surgery: advances in the treatment of motor complications in Parkinson's disease.Drugs in context · 2019Review
- Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.Therapeutic advances in neurological disorders · 2018Review
- Pharmacokinetics of RytaryClinical pharmacokinetics · 2017Review
- Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.Upsala journal of medical sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare plasma levodopa concentrations after repeated doses of levodopa/carbidopa/entacapone (LCE) and levodopa/carbidopa (LC).
methodsOpen-label, randomized, two-period, active-controlled, cross-over study with four dosing regimens: groups I and II (healthy volunteers and Parkinson's disease patients) received levodopa 100 mg or 150 mg four times daily, respectively, and groups III and IV (healthy volunteers) received the same strengths of levodopa five times daily. Pharmacokinetic (PK) parameters determined for levodopa included Cmin, Cmax, Cmax - Cmin, AUC, t(1/2), and tmax.
resultsIn healthy volunteers and PD patients, mean trough levels (Cmin), Cmax, and AUC of levodopa were, in general, significantly higher during LCE compared to LC administration. Compared to Cmin, Cmax, and AUC, differences between the treatments in variability of levodopa concentrations (Cmax - Cmin) were less consistent.
conclusionsThe present results on the differences in levodopa PK between LCE and LC provide a basis to evaluate the relationship of levodopa PK and the induction of motor complications in an on-going study in early Parkinson's disease using similar dosing regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.